Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Equity Income: 2019-2025

Historic Equity Income for BridgeBio Pharma (BBIO) over the last 3 years, with Sep 2025 value amounting to -$15.8 million.

  • BridgeBio Pharma's Equity Income fell 141.26% to -$15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$68.3 million, marking a year-over-year decrease of 164.61%. This contributed to the annual value of -$31.2 million for FY2024, which is N/A change from last year.
  • BridgeBio Pharma's Equity Income amounted to -$15.8 million in Q3 2025, which was up 21.57% from -$20.2 million recorded in Q2 2025.
  • Over the past 5 years, BridgeBio Pharma's Equity Income peaked at -$6.6 million during Q3 2024, and registered a low of -$20.2 million during Q2 2025.
  • Moreover, its 2-year median value for Equity Income was -$15.7 million (2025), whereas its average is -$13.8 million.
  • Data for BridgeBio Pharma's Equity Income shows a maximum YoY crashed of 154.75% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows BridgeBio Pharma's Equity Income stood at -$16.7 million in 2024, then tumbled by 141.26% to -$15.8 million in 2025.
  • Its Equity Income was -$15.8 million in Q3 2025, compared to -$20.2 million in Q2 2025 and -$15.6 million in Q1 2025.